通信電纜 網絡設備 無線通信 云計算|大數據 顯示設備 存儲設備 網絡輔助設備 信號傳輸處理 多媒體設備 廣播系統 智慧城市管理系統 其它智慧基建產品
北京方程嘉鴻科技有限公司
北京方程嘉鴻科技有限公司
北京方程生物公司經營銷售免疫球蛋白A（IgA）ELISA試劑盒，可以提供免費代測，送檢贈京東卡活動正在進行中，詳情咨詢銷售人員
試劑盒名稱:免疫球蛋白A(IgA)
膠原酶I
規格: 96T/48T
品牌:BIOFINE
種屬:人ELISA試劑盒
檢測波長:450nm
所需樣本體積: 50-100ul
適用范圍:僅供科研
保存及有效期:2-8℃，六個月，-20℃一年
檢測目的:用于測定血清，血漿及相關液體免疫球蛋白A(IgA)含量。適合檢測包括血清、血漿、尿液、胸腹水、灌洗液、腦脊液、細胞培養上清、組織勻漿等標本。
本試劑盒采用雙抗體夾心酶聯免疫吸附法定量檢測小鼠TNF-α。小鼠TNF-α試劑盒僅供科學研究，不用于臨床診斷。腫瘤壞死因子 α (TNF-α) 也稱為惡病質素和 TNFSF1A， 是一種脂肪因子，參與全身的炎癥，同時也是刺激急性期反應的細胞因子之一。 它主要由活化的巨噬細胞產生， 也可由其它類型的細胞分泌，如 CD4+ 淋巴細胞、 NK 細胞、 中性粒細胞、 肥大細胞、嗜酸性粒細胞和神經元等。 它在免疫應答中具有多種調節功能， 還可作為潛在的熱原。 TNF-α 對刺激物 (感染因子或組織受損) 產生應答后，在全身循環，激活中性粒細胞，改變血管內皮細胞的特性， 調控其它組織的代謝活性，以及通過誘導局部凝血作用展現腫瘤殺傷活性。 TNF-α 在關節組織和其它組織發生炎癥的發病機制具有重要作用。 zui近，越來越多的信息表明 TNF-α 也參與了 AIDS 的發病機制。 TNF-α 的測定對于移植研究也非常有用。
免疫球蛋白A(IgA)contains the standard concentration of analyte will be prepared. Unknowns that generate a signal that is stronger than the known sample are "positive." Those that generate weaker signal are "negative." Doctor Dennis E Bidwell and Alister Voller created the test. History Before the development of the ELISA, the only option for conducting an immunoassay was radioimmunoassay, a technique using radioactively-labeled antigens or antibodies. In radioimmunoassay, the radioactivity provides the signal, which indicates whether a specific antigen or antibody is present in the sample. Radioimmunoassay was first described in a paper by Rosalyn Sussman Yalow and Solomon Berson published in 1960.[5] Because radioactivity poses a potential health threat, a safer alternative was sought. A suitable alternative to radioimmunoassay would substitute a non-radioactive signal in place of the radioactive signal. When enzymes (such as peroxidase) react with appropriate substrates (such as ABTS or 3,3’,5,5’-Tetramethylbenzidine), a change in color occurs, which is used as a signal. However, the signal has to be associated with the presence of antibody or antigen, which is why the enzyme has to be linked to an appropriate antibody. This linking process was independently developed by Stratis Avrameas and G.B. Pierce.[6] Since it is necessary to remove any unbound antibody or antigen by washing, the antibody or antigen has to be fixed to the surface of the container; i.e., the immunosorbent has to be prepared. A technique to accomplish this was published by Wide and Jerker Porath in 1966.[7] In 1971, Peter Perlmann and Eva Engvall at Stockholm University in Sweden, and Anton Schuurs and Bauke van Weemen in The Netherlands independently published papers that synthesized this knowledge into methods to perform EIA/ELISA.[8][9]
免疫球蛋白A(IgA)
巨噬細胞趨化因子(MCF)
C多肽(CP)
骨成型蛋白7(BMP-7)
血管緊張素Ⅱ受體2(AT2R)
抗副流感病毒IgG抗體(anti-PIV IgG )
阿米巴(Amebiasis)
抗突變型瓜氨酸波形蛋白抗體(MCV)
絲狀血球凝集素(FHA)
低分子肝素(LMWH)
瘦素受體(LEPR)
蛋白Z(Protein Z)
食欲素/阿立新B(OX-B)
您感興趣的產品PRODUCTS YOU ARE INTERESTED IN
智慧城市網 設計制作，未經允許翻錄必究 .? ? ?
請輸入賬號
請輸入密碼
請輸驗證碼
